| Health / Medical Topics |
c-Met Inhibitor JNJ-38877605
An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. c-Met inhibitor JNJ-38877605 selectively inhibits c-Met, a receptor tyrosine kinase (RTK) involved in cancer cell survival and invasiveness, and tumor angiogenesis. c-Met is also known as hepatocyte growth factor receptor (HGFR). (NCI Thesaurus)
YOU MAY ALSO LIKE
An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. c-Met inhibitor…
An orally bioavailable inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor AMG 337 selectively binds to c-Met, thereby disrupting…
A selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor AMG 208 inhibits the ligand-dependent and ligand-independent activation…
A protein found on the surface of many different types of cells. It binds to a substance called stem cell factor (SCF),…
A substance that has been studied in the treatment of cancer and is being studied in the treatment of rheumatoid arthritis and…
An oligonucleotide targeting the c-fos gene which decreases c-fos target mRNA and protein expression, thereby inducing differentiation and inhibiting cell proliferation. …
